P. VIERO; S. CORTELAZZO; M. BUELLI; B. COMOTTI; B. MlNETTI; R. BASSAN; T. BARBUI
This content is PDF only. Please click on the PDF icon to access.
To the editor: Thrombotic thrombocytopenic purpura, a syndrome with a grave prognosis, is characterized by thrombocytopenia, microangiopathic hemolytic anemia, neurologic abnormalities, and fever due to microthrombi formation in the capillaries of almost any tissue. Plasma transfusion and exchange have become the most used therapeutic methods.
The reason for the beneficial effects of this therapeutic procedure is unclear. Normal plasma can supply a factor stimulating release of prostacyclin (1) and factor VIII:von Willebrand factor depolymerase (2). Plasma of some patients with thrombotic thrombocytopenic purpura would contain a platelet-aggregating factor resulting from infectious and noninfectious agents (3, 4), whereas normal plasma would
VIERO P, CORTELAZZO S, BUELLI M, COMOTTI B, MlNETTI B, BASSAN R, et al. Thrombotic Thrombocytopenic Purpura and High-Dose Immunoglobulin Treatment. Ann Intern Med. ;104:282. doi: 10.7326/0003-4819-104-2-282_1
Download citation file:
Published: Ann Intern Med. 1986;104(2):282.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use